A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir [Camvia] for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir [Camvia] for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Maribavir (Primary)
  • Indications Cytomegalic inclusion disorders; Cytomegalovirus infections
  • Focus Therapeutic Use
  • Sponsors Shire; ViroPharma
  • Most Recent Events

    • 02 Jun 2012 Additional locations added as reported by European Clinical Trials Database.
    • 20 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top